Finding new drugs to treat patients hospitalized with COVID-19.

What is the NECTAR Study?
NECTAR is a nationwide research study for people who are hospitalized with COVID-19. The study is looking at new drugs to treat the virus. We want to see if these drugs help you get better by preventing or undoing lung damage caused by COVID-19.

Why is this study important?
People are still becoming sick and hospitalized with COVID-19 and new treatments are needed to help fight the virus. Older adults, rural residents, those with other health conditions, and racially and ethnically diverse groups are more likely to be infected, hospitalized, or die from COVID-19.

It is important to find out if these new drugs help people get better from COVID-19, especially those impacted the most.

What will happen if I join?
If you join the study, you will either receive a study drug or something that looks like the study drug but has no medicine (placebo). You will not know which one you are receiving.

You will:
- Be in the study for about 90 days. You do not need to be in the hospital this entire time.
- Take the study drug as directed.
- Have your blood drawn while you are taking the study drug.
- Allow the study team to see your labs, vital signs, and oxygen levels.

The study team will also contact you after you leave the hospital to see how you are doing.
You will be compensated up to $150 for your time and participation in this study.
Joining the NECTAR Study is voluntary. If you join, you can leave the study at any time.

Why should I join?
You may see improvement in your recovery from COVID-19 by joining this study. This may include survival, faster recovery time, or less need for intensive care. Society may benefit from learning more about the use of these drugs to treat COVID-19.

Where can I join?
This study is currently enrolling at several locations. Visit the study website to learn more!

www.nectarstudy.org